top of page
YooshMD — Online Medical Weight Loss

Medication is the strategic tool

Weight loss medications can be powerful tools when used strategically and under physician supervision. At YooshMD, medication such as Foundayo® is part of a structured metabolic program — not a standalone solution.

GLP-1 receptor analogs

Zepbound® (tirzepatide)

Dual GIP and GLP-1 receptor agonist, enhances satiety, delays gastric emptying, and improves insulin sensitivity.​

Wegovy®, Ozempic®† (semaglutide)

GLP-1 receptor agonist that enhances satiety, delays gastric emptying, and improves glycemic control through glucose-dependent insulin secretion.

Foundayo® (orforglipron)

Partial GLP-1 receptor agonist that enhances satiety, delays gastric emptying, and improves glycemic control through glucose-dependent insulin secretion.

 *If medications are used for reasons other than weight loss (such as diabetes or liver disease), then long-term use is necessary.
†While brand Ozempic® is molecularly identical to Wegovy®, it is technically used off-label for weight loss. 

Appetite suppressants

Contrave® (Bupropion/naltrexone)‡

Norepinephrine and dopamine reuptake inhibitor + mu opioid receptor antagonist. Suppresses appetite and increases energy expenditure via the POMC pathway.

Topiramate

Voltage gated ion channel inhibitor. Suppresses appetite via the NPY/AgRP pathway. This medication is used off-label for weight loss.

Zonisamide

Voltage gated ion channel inhibitor. Suppresses appetite and increases energy expenditure via the POMC pathway. This medication is used off-label for weight loss.

‡Bupriopon and naltrexone may be prescribed separately as an off-label formulation.

Other medications

Metformin

Biguanide that reduces hepatic glucose production and improves peripheral insulin sensitivity. May modestly reduce appetite and improve metabolic efficiency.  This medication is used off-label for weight loss.

Xenical®, Alli® (orlistat)

Gastrointestinal lipase inhibitor that reduces dietary fat absorption by blocking pancreatic and gastric lipases. Decreases caloric intake through partial fat malabsorption.

*Individual results vary. Percentage estimates derived from clinical trial data and may not reflect outcomes in practice. This site does not constitute medical advice.  [Full disclaimers →]

bottom of page